Estrella Immunopharma, Inc. (NASDAQ:ESLA)
| Market Cap | 17.40M-68.6% |
| Revenue (ttm) | 0 |
| Net Income | -10.01M+17.1% |
| EPS | -0.25+25.4% |
| Shares Out | 43.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,095 |
| Open | 0.41 |
| Previous Close | 0.42 |
| Day's Range | 0.40 - 0.43 |
| 52-Week Range | 0.40 - 3.15 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Dec 2, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ESLA
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ESLA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ESLA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ESLA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ESLA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ESLA Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Clinical trial related service fee to related party (Note 5) | $1.38M | 67.16% |
| Professional fee | $289.93K | 14.16% |
| Change in fair value of derivative liabilities | $222.09K | 10.85% |
| Stock-based compensation (Note 8) | $145.30K | 7.10% |
| Consulting fee | $15.00K | 0.73% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ESLA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ESLA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ESLA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $194.74K |
| VXFVanguard Extended Market ETF | $107.48K |
| IWCiShares Micro-Cap ETF | $19.55K |
Estimated from each fund’s disclosed top holdings × AUM
ESLA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ESLA’s recent data — informational, not investment advice